Xiamen, China, September 25-29, 2024 — The 27th National Clinical Oncology Conference and the 2024 Academic Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) commenced in Xiamen, embracing the theme "Patient-Centric, Shared Future." Jointly organized by the CSCO and the CSCO Foundation, the conference has brought together top experts and elites in oncology from both domestic and international fields to discuss the latest advancements, cutting-edge technologies, and future trends in cancer prevention and treatment.Opening Ceremony
The opening ceremony was conducted in an atmosphere brimming with academic enthusiasm.
Professor Xu Ruihua from Sun Yat-sen University Cancer Center, President of CSCO, expressed his gratitude for the contributions of the older generation of oncologists and extended a warm welcome to guests from various fields. He emphasized the conference’s focus on patient-centeredness and the importance of showcasing the depth and breadth of research to promote medical progress.
Academician Cao Xuetao, Deputy Director of the National Health Commission, sent a video message to congratulate the conference and pay tribute to cancer prevention and treatment experts. He underscored the significance of cancer prevention and treatment in enhancing public health and reviewed China’s achievements in these areas.
CSCO Awards
The CSCO Awards Ceremony was a highlight of the event, recognizing outstanding contributions in the field of oncology.
Professor Cheng Ying from Jilin Cancer Hospital received the 2023 Achievement Award for her leadership in the largest international multicenter clinical trial of PD-1 monoclonal antibody in extensive-stage small-cell lung cancer (ES-SCLC), known as the ASTRUM-005 study.
The 2024 Achievement Award was presented to three experts in the fields of respiratory, breast, and digestive oncology: Professor Wu Yilong from Guangdong Provincial People’s Hospital for his work on adjuvant therapy for ALK-positive lung cancer with alectinib; Academician Xu Binghe from the Chinese Academy of Medical Sciences Cancer Hospital for his research on the combination of small molecule TKI pyrotinib with large molecule monoclonal antibodies and chemotherapy for HER2-positive advanced breast cancer; and Professor Xu Ruihua from Sun Yat-sen University Cancer Center for his leadership in international multicenter clinical research that has provided new treatment targets for gastric cancer patients.
The conference also acknowledged the top 10 papers from 1756 submissions with the 2024 CSCO Outstanding Paper Awards.
About CSCO
The Chinese Society of Clinical Oncology (CSCO) is a distinguished organization dedicated to advancing clinical oncology in China. It plays a pivotal role in setting academic standards, nurturing talent, and fostering international cooperation. With a broad membership base, CSCO is a key force in the field of oncology, contributing to the “Healthy China 2030” initiative by enhancing cancer diagnosis and treatment capabilities and improving public health and well-being.
This 2024 CSCO congress featured 67 academic sessions, 506 academic reports, 145 oral presentations, and the release of 14 guidelines, promising a rich academic feast for domestic and international oncology professionals.
